Background and Aims: The standard treatment of non-metastatic anal squamous cell carcinoma (ASCC) consists of chemotherapy with mitomycin (MMC) plus 5-fluorouracil (5FU) for 1–2 cycles concomitant with pelvic radiotherapy. Subsequent studies introduced cisplatin (CDDP) combined with 5FU, with unclear results. We evaluated the doublet capecitabine (C) and CDDP as a possible alternative to MMC-5FU regimen concomitant with intensity-modulated radiation therapy (IMRT). Patients and Methods: We carried out a retrospective study on 67 patients affected by stage I–III ASCC, treated with CDDP (60–70 mg/m2 every 21 days for two courses) plus C (825 mg/m2 twice daily for 5 days/week) chemotherapy concomitant with IMRT for curative intent. Results: At a median follow up of 41 months, the clinical complete response calculated at the 6-month time-point (6-moCR), the 6-month objective response rate and the 6-month disease control rate were 93%, 94%, and 99%, respectively. Disease-free survival rates at 1, 2, and 3 years were 89%, 87%, and 85%, while the overall survival rates at 1 and 2 years were 100% and 95%. The colostomy-free survival rates were 90% at 1 year and 88% at 2 years. Grade 3–4 acute adverse events were reported in 61% of patients; predominantly skin toxicity (46%) and limited hematological toxicity (12%). Conclusion: In this retrospective study, chemotherapy with C plus CDDP concomitant with IMRT proved safe and effective, and may represent a possible alternative option to standard MMC-containing regimen for curative intent.
Rotundo, M., Zampino, M., Ravenda, P., Bagnardi, V., Peveri, G., Dell'Acqua, V., et al. (2020). Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12.
Citazione: | Rotundo, M., Zampino, M., Ravenda, P., Bagnardi, V., Peveri, G., Dell'Acqua, V., et al. (2020). Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12. | |
Tipo: | Articolo in rivista - Articolo scientifico | |
Carattere della pubblicazione: | Scientifica | |
Presenza di un coautore afferente ad Istituzioni straniere: | No | |
Titolo: | Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center | |
Autori: | Rotundo, M; Zampino, M; Ravenda, P; Bagnardi, V; Peveri, G; Dell'Acqua, V; Surgo, A; Trovato, C; Bottiglieri, L; Bertani, E; Petz, W; Fumagalli Romario, U; Fazio, N | |
Autori: | ||
Data di pubblicazione: | 2020 | |
Lingua: | English | |
Rivista: | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1177/1758835920940945 | |
Appare nelle tipologie: | 01 - Articolo su rivista |